Tags

Type your tag names separated by a space and hit enter

Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
Vaccine. 2013 Feb 27; 31(10):1385-92.V

Abstract

The present study demonstrates the cross-protective efficacy of baculovirus displayed HAs of A/Indonesia/669/06 and A/Anhui/01/05 against heterologous H5N1 challenges in a mouse model. Mice orally or subcutaneously immunized with live bivalent-BacHA vaccine significantly induced higher HA-specific humoral and cellular immune responses when compared with inactivated bivalent-BacHA. In addition, oral administration of live bivalent-BacHA vaccine was able to induce significant level of antigen-specific mucosal IgA levels. Microneutralization assay indicated that live bivalent-BacHA vaccine was able to induce strong cross-clade neutralization titer against distinct H5N1 clades (1, 2.1.3, 2.2.1.1, 2.3.2, 2.3.4, 4, 7 and 9). The production of both interferon-gamma (IFN-γ) and interleukin-4 (IL-4) by splenocytes from vaccinated mice indicated that mice vaccinated orally or subcutaneously with live bivalent-BacHA stimulated both IFN-γ secreting Th1 cells and IL-4 secreting Th2 cells, whereas mice immunized subcutaneously with inactive adjuvanted bivalent-BacHA stimulated only IL-4 secreting Th2 cells. Cross-protective immunity study also showed that mice immunized either orally or subcutaneously with live bivalent-BacHA were completely protected against 5MLD50 of clade 1 and clade 2.2.1.1 H5N1 viral infections. The protective immune response elicited by bivalent-BacHA vaccine against H5N1 variants demonstrates the possibility of protection against a broad range of H5N1 strains.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Prabakaran M
Animal Health Biotechnology, Temasek Life Sciences Laboratory, National University of Singapore, Singapore 117604, Singapore.
Kolpe AB
No affiliation info available
He F
No affiliation info available
Kwang J
No affiliation info available

MeSH

Administration, OralAnimalsAntibodies, NeutralizingAntibodies, ViralBaculoviridaeCross ProtectionDisease Models, AnimalDrug CarriersFemaleGenetic VectorsHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesInjections, SubcutaneousInterferon-gammaMiceMice, Inbred BALB COrthomyxoviridae InfectionsT-LymphocytesVaccines, Synthetic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23328313

Citation

Prabakaran, Mookkan, et al. "Cross-protective Efficacy of Bivalent Recombinant Baculoviral Vaccine Against Heterologous Influenza H5N1 Challenge." Vaccine, vol. 31, no. 10, 2013, pp. 1385-92.
Prabakaran M, Kolpe AB, He F, et al. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine. 2013;31(10):1385-92.
Prabakaran, M., Kolpe, A. B., He, F., & Kwang, J. (2013). Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine, 31(10), 1385-92. https://doi.org/10.1016/j.vaccine.2013.01.003
Prabakaran M, et al. Cross-protective Efficacy of Bivalent Recombinant Baculoviral Vaccine Against Heterologous Influenza H5N1 Challenge. Vaccine. 2013 Feb 27;31(10):1385-92. PubMed PMID: 23328313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. AU - Prabakaran,Mookkan, AU - Kolpe,Annasaheb B, AU - He,Fang, AU - Kwang,Jimmy, Y1 - 2013/01/14/ PY - 2012/07/30/received PY - 2012/12/26/revised PY - 2013/01/01/accepted PY - 2013/1/19/entrez PY - 2013/1/19/pubmed PY - 2013/8/13/medline SP - 1385 EP - 92 JF - Vaccine JO - Vaccine VL - 31 IS - 10 N2 - The present study demonstrates the cross-protective efficacy of baculovirus displayed HAs of A/Indonesia/669/06 and A/Anhui/01/05 against heterologous H5N1 challenges in a mouse model. Mice orally or subcutaneously immunized with live bivalent-BacHA vaccine significantly induced higher HA-specific humoral and cellular immune responses when compared with inactivated bivalent-BacHA. In addition, oral administration of live bivalent-BacHA vaccine was able to induce significant level of antigen-specific mucosal IgA levels. Microneutralization assay indicated that live bivalent-BacHA vaccine was able to induce strong cross-clade neutralization titer against distinct H5N1 clades (1, 2.1.3, 2.2.1.1, 2.3.2, 2.3.4, 4, 7 and 9). The production of both interferon-gamma (IFN-γ) and interleukin-4 (IL-4) by splenocytes from vaccinated mice indicated that mice vaccinated orally or subcutaneously with live bivalent-BacHA stimulated both IFN-γ secreting Th1 cells and IL-4 secreting Th2 cells, whereas mice immunized subcutaneously with inactive adjuvanted bivalent-BacHA stimulated only IL-4 secreting Th2 cells. Cross-protective immunity study also showed that mice immunized either orally or subcutaneously with live bivalent-BacHA were completely protected against 5MLD50 of clade 1 and clade 2.2.1.1 H5N1 viral infections. The protective immune response elicited by bivalent-BacHA vaccine against H5N1 variants demonstrates the possibility of protection against a broad range of H5N1 strains. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/23328313/Cross_protective_efficacy_of_bivalent_recombinant_baculoviral_vaccine_against_heterologous_influenza_H5N1_challenge_ DB - PRIME DP - Unbound Medicine ER -